Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 359 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Zyban Clear all

Conditions: Pancreatitis, Chronic, Pancreatitis, Acute, Recurrent Acute Pancreatitis, Smoking (Tobacco) Addiction
Interventions: Standard Varenicline Dosing (1 mg BID), Bupropion 150 mg twice daily, Increased Varenicline Dosing (1mg TID); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Low Back Pain, Negative Affectivity
Interventions: Antidepressant, Enhanced Fear Avoidance Rehabilitation; Drug · Other
Lead sponsor: Ajay Wasan, MD, Msc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Chestnut Hill, Massachusetts • Rochester, Minnesota • Pittsburgh, Pennsylvania

Conditions: Smoking Cessation
Interventions: Tobacco Tactics Intervention, Usual Care; Behavioral · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 1,528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 6
States / cities: Grand Rapids, Michigan • Livonia, Michigan • Muskegon, Michigan + 2 more

Conditions: Major Depressive Disorder, Healthy Controls
Interventions: Any FDA Approved Antidepressant; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Methamphetamine
Interventions: Bupropion, Placebo; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Los Angeles, California • Rancho Cucamonga, California

Conditions: Obesity
Interventions: Naltrexone-Bupropion (NB) Combination, Placebo; Drug
Lead sponsor: Currax Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 8,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 140
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 111 more

Conditions: Tobacco-Use Disorder, Schizophrenia, Psychotic Disorders
Interventions: bupropion SR, Cognitive Behavioral Group Therapy, nicotine replacement therapy; Drug · Behavioral
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Treatment Resistant Major Depressive Disorder
Interventions: AXS-05, Bupropion; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 74
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 71 more

Conditions: Cigarette Smoking, Nicotine Dependence
Interventions: varenicline (Chantix), bupropion (Zyban), nicotine patches; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Durham, North Carolina • Raleigh, North Carolina

Conditions: Schizophrenia, Smoking Cessation
Interventions: Sugar Pill, Varenicline, Bupropion HCl; Other · Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bipolar Disorder
Interventions: lithium, valproate, bupropion, paroxetine, lamotrigine, risperidone, inositol, tranylcypromine, Cognitive Behavioral Therapy, Family-focused Therapy, Interpersonal and Social Rhythms Therapy; Drug · Behavioral
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 15 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 11
States / cities: Stanford, California • Denver, Colorado • Boston, Massachusetts + 8 more

Conditions: Depression, Palliative Care, Cancer, Mental Disorder
Interventions: Methylphenidate, Placebo, Selective Serotonin Uptake Inhibitor (SSRI); Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Substance Abuse, Cocaine Dependence
Interventions: Placebo, Bupropion XL, Abstinence Initiation, Relapse Prevention; Drug · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2021
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Depression
Interventions: Escitalopram, Bupropion; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Obesity, Overweight
Interventions: Behavioral Weight Loss (BWL), Early Responder: BWL continued, Early Non-responder: BWL continued with medication added; Behavioral · Combination Product
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Nicotine Dependence
Interventions: Varenicline, Bupropion, Nicotine patches, Nicotine Inhaler; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Charlotte, North Carolina • Durham, North Carolina • Raleigh, North Carolina + 1 more

Conditions: Healthy
Interventions: Abrika Bupropion 150 mg XL Tablet, single dose, Wellbutrin XL® 150 mg Tablet, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Tuberculosis, Tuberculosis, Pulmonary
Interventions: TBA-7371, Placebo; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Obesity, Cardiovascular Diseases
Interventions: Naltrexone HCl/Bupropion HCl ER, Placebo; Drug
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 139
States / cities: Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more

Conditions: Major Depressive Disorder (MDD)
Interventions: Extended-release Bupropion Hydrochloride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 24
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 19 more

Conditions: Lung Non-Small Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions: Nicotine Replacement, Bupropion Hydrochloride Controlled-release, Varenicline, Tobacco Cessation Counseling, Questionnaire Administration, Quality of Life Assessment, Best Practice; Drug · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Methamphetamine-dependence, Methamphetamine Abuse
Interventions: extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB, oPLB; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Little Rock, Arkansas • Los Angeles, California • San Diego, California + 8 more

Conditions: Unipolar Depression
Interventions: Rispridone (drug) and Bupropion ER (drug); Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: ADHD, Opioid-Related Disorders, Cocaine Dependence
Interventions: Methylphenidate, Bupropion, Placebo; Drug · Other
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis

Treating Negative Affect in Low Back Pain Patients

Dissemination of Tobacco Tactics for Hospitalized Smokers

Effects of Treatment on Decision-making in Major Depression

Effectiveness of Bupropion Combined With Behavioral Therapy for Treating Methamphetamine Dependence - 2

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder

Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants

Varenicline and Smoking Cessation in Schizophrenia

Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence

Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression

Weight Regain Treatment Post-Bariatric Surgery

Concurrent Bupropion / Varenicline for Smoking Cessation

A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions

A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371

Naltrexone/Bupropion Cardiovascular Outcomes Study

Effects Of Antidepressants On Sexual Functioning In Adults

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression

Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1